Lab
Boston Heart Diagnostics Corporation
Boston Heart Diagnostics Corporation was paid $10.37M by Medicaid between Jan 2018 and Nov 2024, across 82 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 80% of everything it billed.
33Billing provider infoBOSTON HEART DIAGNOSTICS CORPORATION
FRAMINGHAM, MA 01702
FRAMINGHAM, MA 01702
33aNPI1922259753assigned 10/10/2008
33bProvider typeClinical Medical Laboratory
28Total paid$10.37M
24GClaims361,075
24DCodes billed82
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Massachusetts
Rank by total paid#7 of 63
Median peer was paid$473K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54,345 | $463K | |
| 2019 | 43,910 | $280K | |
| 2020 | 95,478 | $4.61M | |
| 2021 | 123,815 | $4.40M | |
| 2022 | 25,102 | $530K | |
| 2023 | 11,274 | $51K | |
| 2024incomplete | 7,151 | $35K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 80% | 136,792 | 127,262 | $8.27M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 7.2% | 39,584 | 37,499 | $744K |
| 86769 | 2.2% | 8,431 | 5,459 | $227K | |
| 83519 | 2.1% | 9,596 | 8,837 | $213K | |
| 83921 | 1.0% | 12,963 | 8,791 | $106K | |
| 82172 | <1% | 5,889 | 5,456 | $76K | |
| 83701 | <1% | 5,996 | 5,523 | $70K | |
| 82725 | <1% | 8,730 | 7,951 | $51K | |
| 83876 | <1% | 4,808 | 4,436 | $44K | |
| 81401 | <1% | 696 | 612 | $39K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,869 | 4,475 | $39K |
| 80061 | Lipid panel | <1% | 7,491 | 6,845 | $31K |
70 more codes
| 86141 | <1% | 8,076 | $30K | |
| 83695 | <1% | 6,224 | $25K | |
| 83520 | <1% | 5,580 | $24K | |
| 82985 | <1% | 2,705 | $22K | |
| 83525 | <1% | 5,204 | $20K | |
| 83880 | <1% | 2,241 | $20K | |
| 83698 | <1% | 5,350 | $19K | |
| 83090 | <1% | 3,532 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,076 | $16K |
| 82670 | <1% | 1,745 | $15K | |
| 84403 | <1% | 1,974 | $15K | |
| 81241 | <1% | 397 | $15K | |
| 81240 | <1% | 350 | $13K | |
| 83704 | <1% | 1,167 | $13K | |
| 83722 | <1% | 4,350 | $12K | |
| 82627 | <1% | 1,748 | $12K | |
| 82542 | <1% | 2,335 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,041 | $11K |
| 84481 | <1% | 1,686 | $11K | |
| 80053 | Comprehensive metabolic panel | <1% | 3,383 | $10K |
| 82607 | <1% | 2,749 | $10K | |
| 84144 | <1% | 1,247 | $9K | |
| 81328 | <1% | 1,112 | $9K | |
| 85385 | <1% | 2,706 | $8K | |
| 83721 | <1% | 3,352 | $8K | |
| 82746 | <1% | 1,792 | $6K | |
| 83002 | <1% | 942 | $6K | |
| 84439 | <1% | 1,938 | $6K | |
| 82728 | <1% | 1,408 | $5K | |
| 83001 | <1% | 809 | $5K | |
| 84681 | <1% | 960 | $5K | |
| 81291 | <1% | 444 | $4K | |
| 81400 | <1% | 88 | $4K | |
| 82947 | <1% | 2,340 | $4K | |
| 84270 | <1% | 523 | $4K | |
| 82550 | <1% | 2,515 | $3K | |
| 83735 | <1% | 2,376 | $3K | |
| 82610 | <1% | 1,468 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,290 | $3K |
| 84550 | <1% | 3,028 | $2K | |
| 82533 | <1% | 339 | $2K | |
| 83540 | <1% | 1,200 | $2K | |
| 85027 | <1% | 600 | $2K | |
| 86376 | <1% | 230 | $2K | |
| 83718 | <1% | 586 | $1K | |
| 84478 | <1% | 1,529 | $1K | |
| 83550 | <1% | 673 | $1K | |
| 80050 | General health panel | <1% | 120 | $1K |
| 82040 | <1% | 950 | $1K | |
| 82248 | <1% | 545 | $931.46 | |
| 83970 | <1% | 62 | $850.81 | |
| 84460 | <1% | 943 | $831.15 | |
| 84075 | <1% | 914 | $765.36 | |
| 84450 | <1% | 818 | $749.56 | |
| 84484 | <1% | 288 | $748.03 | |
| 82565 | <1% | 869 | $739.40 | |
| 82088 | <1% | 121 | $716.70 | |
| 81225 | <1% | 44 | $555.80 | |
| 84520 | <1% | 784 | $509.65 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 197 | $468.37 |
| 84153 | <1% | 81 | $412.08 | |
| 84100 | <1% | 622 | $307.66 | |
| 84431 | <1% | 213 | $248.94 | |
| 82043 | <1% | 357 | $162.61 | |
| 86800 | <1% | 14 | $139.93 | |
| 86408 | <1% | 12 | $115.44 | |
| 82570 | <1% | 671 | $105.62 | |
| 82977 | <1% | 37 | $67.73 | |
| 84132 | <1% | 105 | $27.46 | |
| 80051 | <1% | 55 | $9.19 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialURBANEK, MATTHEW (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Eurofins NTD LLC | Melville, NY | $5.05M |
| Eurofins Transplant Genomics, LLC | Lenexa, KS | $483K |
| Transplant Genomics, INC. | Fremont, CA | $332K |
| Clinical Enterprise INC | Framingham, MA | $127K |
| Eurofins Viracor LLC | Lenexa, KS | $64K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.